|
Delayed
Toronto S.E.
09:36:55 2026-07-06 EDT
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | -.--% |
|
-.--% | -40.00% |
| Market Cap | 918K 662K 572K 537K 488K 63.28M 934K 6.29M 2.46M 31.69M 2.48M 2.43M 105M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92M 1.38M 1.19M 1.12M 1.02M 132M 1.95M 13.14M 5.14M 66.17M 5.19M 5.08M 220M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -25.00% | ||
| 6 months | -25.00% | ||
| Current year | -40.00% |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.2 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 2018-08-02 |
Mahmoud Aziz
PSD | President | - | 2021-05-20 |
Danny Wayne Lee
DFI | Director of Finance/CFO | - | 2020-12-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 2018-08-02 |
Jamie Lewin
BRD | Director/Board Member | 76 | 2019-03-10 |
Kevin Bottomley
BRD | Director/Board Member | 44 | 2019-09-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -57.14% | -75.00% | 659K | ||
| -0.10% | -1.08% | +17.70% | +70.44% | 48.57B | ||
| -3.26% | -1.15% | +50.36% | +115.32% | 40.99B | ||
| -0.60% | -1.83% | -7.11% | +15.98% | 12.35B | ||
| -2.75% | +2.45% | +14.83% | +74.39% | 12.2B | ||
| -0.19% | -0.19% | +29.10% | +135.91% | 9.08B | ||
| +1.56% | +5.52% | +23.46% | +39.78% | 7.41B | ||
| +0.52% | +3.93% | +39.82% | -13.06% | 7.13B | ||
| -0.07% | +2.13% | +14.25% | +189.31% | 6.86B | ||
| -2.51% | +3.10% | -27.59% | +27.09% | 5.92B | ||
| Average | -0.74% | +1.35% | +9.77% | +58.02% | 15.05B | |
| Weighted average by Cap. | -1.20% | +1.03% | +24.41% | +80.72% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.46 | - |
| Net income | -73.2K -52.75K -45.56K -42.81K -38.93K -5.04M -74.4K -502K -196K -2.53M -198K -194K -8.39M | -335K -241K -209K -196K -178K -23.09M -341K -2.3M -898K -11.56M -906K -887K -38.42M |
| Net Debt | 804K 579K 501K 470K 428K 55.41M 817K 5.51M 2.15M 27.75M 2.18M 2.13M 92.21M | 999K 720K 622K 584K 532K 68.86M 1.02M 6.85M 2.68M 34.48M 2.7M 2.64M 115M |
Employees
4,000
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















